The 100 mg/mL formulation of ULTOMIRIS—a long-acting C5 inhibitor administered every eight weeks offering immediate, complete and sustained complement inhibition—was evaluated to determine if participants with paroxysmal nocturnal hemoglobinuria (PNH) could achieve greater convenience by reducing infusion times, thus lessening demands on the healthcare system.The U.S. Food and Drug Administration (FDA) is currently reviewing the company’s supplemental biologics application for the ULTOMIRIS 100mg/mL formulation for the treatment of atypical hemolytic uremic syndrome (aHUS) and for adults with PNH.